Kymera Therapeutics Investor Relations Material
Latest events
Q1 2025
Kymera Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Kymera Therapeutics Inc
Access all reports
Kymera Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapies. The company’s proprietary platform aims to design small-molecule drugs that selectively degrade disease-causing proteins, offering a novel approach to treating conditions that have been difficult to address with traditional therapies. Kymera Therapeutics is engaged in research and development across various therapeutic areas, including oncology, immunology, and inflammation. The company is headquartered in Watertown, United States, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
KYMR
Country
🇺🇸 United States